Advertisement
Screener

TRAVERE THERAPEUTICS, INC. (TVTX) Operating Leases, Future Minimum Payments, Due in Rolling after Year Five

3.1 / 5 stars · 22/36 Roast Me

TRAVERE THERAPEUTICS, INC. Operating Leases, Future Minimum Payments, Due in Rolling after Year Five

TRAVERE THERAPEUTICS, INC. (TVTX) had Operating Leases, Future Minimum Payments, Due in Rolling after Year Five of $4.22 million as of 2017-12-31, per its 10-K filed 2018-07-06.

Discontinued › Notes › Leases

us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive · last filed 2018-07-06

  • 2017-12-31: Operating Leases, Future Minimum Payments, Due in Rolling after Year Five $4.22M.
  • 2017-09-30: Operating Leases, Future Minimum Payments, Due in Rolling after Year Five $4.86M.
  • 2017-06-30: Operating Leases, Future Minimum Payments, Due in Rolling after Year Five $806.00K.
  • 2017-03-31: Operating Leases, Future Minimum Payments, Due in Rolling after Year Five $2.15M.
Period endOperating Leases, Future Minimum Payments, Due in Rolling after Year FiveOperating Leases, Future Minimum Payments, Due in Rolling after Year Five as first filed
2017-12-31$4.22M
10-K · filed 2018-07-06
2017-09-30$4.86M
10-Q · filed 2017-11-07
2017-06-30$806.00K
10-Q · filed 2017-08-09
2017-03-31$2.15M
10-Q · filed 2017-05-05
2016-09-30$5.02M
10-Q · filed 2016-11-04
2016-06-30$0.00
10-Q · filed 2016-08-05
2016-03-31$0.00
10-Q · filed 2016-05-05
2015-12-31$3.45M
10-K · filed 2017-03-01
$0.00
10-K · filed 2016-02-26
2015-09-30$0.00
10-Q · filed 2015-11-06

Similar stocks

Stock NameCountryMarket CapPE Ratio
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Cogent Biosciences, Inc. (COGT)United States$5.450B-17.61
Gossamer Bio, Inc. (GOSS)United States$5.355B-0.65
PTC THERAPEUTICS, INC. (PTCT)United States$5.199B-177.07
Amneal Pharmaceuticals, Inc. (AMRX)$6.326B25.62
Dianthus Therapeutics, Inc. /DE/ (DNTH)United States$5.082B-27.79
Liquidia Corp (LQDA)United States$6.347B51.23
Erasca, Inc. (ERAS)United States$5.073B-19.96
Veradermics, Inc (MANE)United States$4.839B